Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prilocaine + felypressin is a combination local anesthetic and vasoconstrictor formulation used primarily in dentistry. Prilocaine is an amide-type local anesthetic that works by blocking voltage-gated sodium channels in nerve cell membranes, thereby preventing the initiation and conduction of nerve impulses and providing pain relief. Felypressin is a synthetic analogue of the hormone vasopressin that acts as a non-catecholamine vasoconstrictor by stimulating V1 receptors on vascular smooth muscle. This combination is particularly advantageous for patients with cardiovascular disease or other conditions where epinephrine (adrenaline) is contraindicated. A Phase 4 clinical trial conducted by Taibah University evaluated the efficacy of a 3% prilocaine and 0.03 I.U./ml felypressin formulation for the extraction of maxillary teeth, finding it to be as effective as 4% articaine with epinephrine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on prilocaine + felypressin.